Medicenna Therapeutics Corp. ( MDNA) Stock. Should you Buy or Sell? $ 0.97
0.01 (0.50 %)
Medicenna Therapeutics Corp. AnalysisUpdated on 10-09-2022
|Volume Avg.||$287.77 thousand|
|Market Cap||$67.67 M|
|52 Week Range||$0.76 - $2.94|
Medicenna Therapeutics Corp. opened the day at $0.97 which is +'0.50 % on yesterday's close. Medicenna Therapeutics Corp. has a 52 week high of $2.94 and 52 week low of $0.76, which is a difference of $2.18. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $67.67 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Medicenna Therapeutics Corp. for $67.67 M, it would take 15 years to get your money back. Medicenna Therapeutics Corp. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Medicenna Therapeutics Corp. Stock Forecast - Is Medicenna Therapeutics Corp. a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||0.000|
Valuing Medicenna Therapeutics Corp.
|Price Book Value Ratio||3.822||Price To Book Ratio||3.822|
|Price To Sales Ratio||0.000||Price Earnings Ratio||-3.380|
How liquid is Medicenna Therapeutics Corp.
|Debt Ratio||0.107||Debt Equity Ratio||0.119|
|Long Term Debt To Capitalization||0.000||Total Debt To Capitalization||0.000|
Latest news about Medicenna Therapeutics Corp.
Penny stocks are shares usually below $5, representing small companies, most of which trade by over-the-counter (OTC) transactions, while there
Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q1 2023 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Arthur He - H.C. Wainwright Operator Greetings, and welcome to the Medicenna Therapeutics Corp. First Quarter Fiscal 2023 Earnings Call.
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights.
Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Fahar Merchant - President & CEO Martin Bexon - CMO Liz Williams - CFO Conference Call Participants Matt Biegler - Oppenheimer David Martin - Bloom Burton Catherine Novack - JonesTrading Swayampakula Ramakanth - H.C. Wainwright Andre Uddin - Mackie Research Capital Shubhendu Roy - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Hello, and welcome to the Medicenna Therapeutics Fiscal Year-End Earnings Call.
TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights.
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.